Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

Vir Biotechnology, Inc.

Filed: Jun 9, 2026CIK: 0001706431
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Vir Biotechnology appointed Timothy Coughlin, CPA, to its Board of Directors on June 9, 2026, expanding the board from seven to eight members. Coughlin was also named Chair of the Audit Committee, strengthening the company's financial governance and oversight capabilities.

Key Takeaways

Timothy Coughlin, CPA, appointed as new Class III director, serving until the 2028 annual stockholder meeting

Board size expanded from seven to eight members to accommodate the new appointment

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 9, 2026
Item5.02
CategoryExecutive Change
CIK0001706431
Accession #vir-20260609
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board change

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings